Frequency of vaccine-related reactogenicity events (REs) that occur during the acute monitoring phase of the study (Days 0 to 10 for adult and seropositive groups, Days 0 to 28 for seronegative groups) Throughout study [clinicaltrials_resource:c590279c48348c96d7a25752a00ffbda]
One vaccination with rB/HPIV3 vaccine (at higher dose) given as nose drops to adults 18 to 49 years of age
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Frequency of vaccine-related reactogenicity events (REs) that occur during the acute monitoring phase of the study (Days 0 to 10 for adult and seropositive groups, Days 0 to 28 for seronegative groups) Throughout study [clinicaltrials_resource:c590279c48348c96d7a25752a00ffbda]
One vaccination with rB/HPIV3 vaccine (at higher dose) given as nose drops to adults 18 to 49 years of age
Bio2RDF identifier
c590279c48348c96d7a25752a00ffbda
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:c590279c48348c96d7a25752a00ffbda
measure [clinicaltrials_vocabulary:measure]
Frequency of vaccine-related r ...... to 28 for seronegative groups)
time frame [clinicaltrials_vocabulary:time-frame]
Throughout study
description
One vaccination with rB/HPIV3 ...... o adults 18 to 49 years of age
identifier
clinicaltrials_resource:c590279c48348c96d7a25752a00ffbda
title
Frequency of vaccine-related r ...... ative groups) Throughout study
@en
type
label
Frequency of vaccine-related r ...... 0279c48348c96d7a25752a00ffbda]
@en